Innovating Works

SMARTRIOX

Financiado
Disruptive targeted drug delivery system via synergistic combination of intellig...
Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles Although there are Triple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic... Although there are Triple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2+ and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC. ver más
31/10/2021
Triox Nano Ltd
3M€
Duración del proyecto: 41 meses Fecha Inicio: 2018-05-25
Fecha Fin: 2021-10-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-10-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
TRIOX NANO LTD No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5